years and high prevalences of hypertension (75%), diabetes mellitus, dyspnea, previous heart failure, and peripheral vascular disease, all factors associated with a higher risk of AKI. Although the mean estimated glomerular filtration rate (GFR) was not unreasonable, w10% of patients had severe baseline renal dysfunction (estimated GFR <30 ml/min), and almost 50% had moderate renal dysfunction (estimated GFR 30 to 60 ml/min). The TAVR procedures themselves (majority CoreValve) were well executed by this experienced group with high device success rates and a low incidence of permanent pacemaker implantation. Rapid pacing, which induces hypotension, was used in all cases, and the median contrast volume administered was relatively high at 175 ml (interquartile range up to 230 ml).
The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation)* only at risk of AKI but of subsequent cardiac and noncardiac mortality. In the current study, patients were quite typical of those undergoing TAVR in Europe and North America, with a median age older than 80 years and high prevalences of hypertension (75%), diabetes mellitus, dyspnea, previous heart failure, and peripheral vascular disease, all factors associated with a higher risk of AKI. Although the mean estimated glomerular filtration rate (GFR) was not unreasonable, w10% of patients had severe baseline renal dysfunction (estimated GFR <30 ml/min), and almost 50% had moderate renal dysfunction (estimated GFR 30 to 60 ml/min). The TAVR procedures themselves (majority CoreValve) were well executed by this experienced group with high device success rates and a low incidence of permanent pacemaker implantation. Rapid pacing, which induces hypotension, was used in all cases, and the median contrast volume administered was relatively high at 175 ml (interquartile range up to 230 ml). Clinic, Rochester, Minnesota. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. What, then, can we conclude from the current paper? First, the RenalGuard system appears to be safe to use in patients undergoing TAVR and is associated with lower creatinine increases, but there are no differences in important clinical endpoints, including need for hemodialysis. We are not convinced that serum creatinine is an appropriate sole marker for AKI when a renal flushing system is being used for the reasons outlined previously.
Finally, the RenalGuard system should be evaluated kidney injury molecule-1 [6] ). Until such trials are performed, we believe that it is premature to advocate widespread adoption of renal flushing for the prevention of AKI.
